About this trial
Echocardiographic Assessment:
Performed within 24h of PE diagnosis Conventional parameters: TAPSE, RV FAC, RV/LV ratio, tricuspid S', PASP STE parameters: RV free wall longitudinal strain (RVFWS), global longitudinal strain (GLS) if feasible All measurements averaged over 3 cardiac cycles (sinus) or 5 (AF)
Follow-up data:
ICU/hospital LOS Need for vasopressors/mechanical ventilation In-hospital and 30-day mortality
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adults ≥18 years.
Confirmed acute PE (via CT pulmonary angiography).(4,6)
Echocardiography performed within 24 hours of diagnosis.
Disqualifiers
Pre-existing significant RV dysfunction (e.g., due to chronic pulmonary hypertension, cor pulmonale or congenital heart disease).
History of coronary artery disease.
Impaired LV systolic function, ejection fraction <50%.
Moderate to severe valvular heart disease.
Trial population
patients aged more than 18 years old with confirmed pulmonary embolism
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Primary (main): Composite of in-hospital mortality, ICU admission >7 days, or need for mechanical circulatory/ventilatory support.
Secondary outcomes
Secondary outcome: Each individual component; echocardiographic parameters as predictors.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: